RxDoctor Payments Data

Catherine Cunningham, DO

Hospitalist · Clarion, PANPI 1760458244

Payments from drug & device makers

$772in general payments, 2019–2025

Across 32 payments — averaging $24.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$143
  • E.r. Squibb & Sons, L.L.C.$140
  • Madrigal Pharmaceuticals$114
  • Astellas Pharma US Inc$104
  • Boston Scientific$77
  • Grifols USA, LLC$37
  • plus $157 from 7 others

What the payments were for

  • Food & beverage$66286%
  • Education$11014%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$772 in reported general payments places this provider in the 85th percentile of 1,287 hospitalist providers in Pennsylvania.

See all hospitalist providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$52,332
Medicare patients
176
Services billed
501

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban48$20,167
TradjentaLinagliptin43$11,318
JardianceEmpagliflozin28$10,310
Trelegy ElliptaFluticasone/Umeclidin/Vilanter11$7,657
Theophylline ErTheophylline Anhydrous11$1,093
Rosuvastatin Calcium12$1,042
Diltiazem 24hr Er (La)Diltiazem Hcl22$1,017
Pravastatin Sodium21$432
Levothyroxine Sodium27$422
Bumetanide22$351
Gabapentin22$295
Duloxetine Hcl24$257
Baclofen12$245
Tolterodine Tartrate11$237
Atorvastatin Calcium22$233

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimTradjenta, Jardiance$31$21,62871 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,287 hospitalist providers in Pennsylvania.

Other hospitalist in Clarion

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →